Follow the people · Insider
Darin Lippoldt
Darin Lippoldt files insider transactions with the SEC as a chief legal officer of Neurocrine Biosciences (NBIX). We hold 3 disclosed purchases and sales filed since 17 February 2011, 3 of them in the last 90 days.
- Files forNBIX
- Disclosed buys and sells3 in all, 3 in the last 90 days
- Last disclosure13 July 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 3 November 2014 — 9 July 2026Chief Legal Officer · Neurocrine Biosciences (NBIX)233 Form 4 lines · source: SEC Form 4
- Filed 15 February 2011 — 19 March 2014EVP, General Counsel · Volcano (VOLC)45 Form 4 lines · source: SEC Form 4
Everything they disclosed
120 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 10,000 shares of Neurocrine BiosciencesSEC Form 413 July 2026Common Stock · traded 9 July 2026 · filed 13 July 2026
- ▼ sold on the open market 10,000 shares of Neurocrine BiosciencesSEC Form 413 July 2026Common Stock · traded 9 July 2026 · filed 13 July 2026
- exercised options over 10,000 shares of Neurocrine Biosciences (a derivative holding)SEC Form 413 July 2026Non-Qualified Stock Option · traded 9 July 2026 · filed 13 July 2026
- exercised options over 200 shares of Neurocrine BiosciencesSEC Form 430 June 2026Common Stock · traded 26 June 2026 · filed 30 June 2026
- ▼ sold on the open market 200 shares of Neurocrine BiosciencesSEC Form 430 June 2026Common Stock · traded 26 June 2026 · filed 30 June 2026
- exercised options over 8,110 shares of Neurocrine BiosciencesSEC Form 430 June 2026Common Stock · traded 29 June 2026 · filed 30 June 2026
- ▼ sold on the open market 8,110 shares of Neurocrine BiosciencesSEC Form 430 June 2026Common Stock · traded 29 June 2026 · filed 30 June 2026
- exercised options over 1,690 shares of Neurocrine BiosciencesSEC Form 430 June 2026Common Stock · traded 29 June 2026 · filed 30 June 2026
- ▼ sold on the open market 1,690 shares of Neurocrine BiosciencesSEC Form 430 June 2026Common Stock · traded 29 June 2026 · filed 30 June 2026
- exercised options over 200 shares of Neurocrine Biosciences (a derivative holding)SEC Form 430 June 2026Non-Qualified Stock Option · traded 26 June 2026 · filed 30 June 2026
- exercised options over 8,110 shares of Neurocrine Biosciences (a derivative holding)SEC Form 430 June 2026Non-Qualified Stock Option · traded 29 June 2026 · filed 30 June 2026
- exercised options over 1,690 shares of Neurocrine Biosciences (a derivative holding)SEC Form 430 June 2026Non-Qualified Stock Option · traded 29 June 2026 · filed 30 June 2026
- exercised options over 1,792 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 12 February 2026 · filed 17 February 2026
- exercised options over 1,792 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Restricted Stock Unit · traded 12 February 2026 · filed 17 February 2026
- exercised options over 2,017 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Restricted Stock Unit · traded 13 February 2026 · filed 17 February 2026
- exercised options over 2,083 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Restricted Stock Unit · traded 13 February 2026 · filed 17 February 2026
- was granted 34,909 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Stock Option · traded 13 February 2026 · filed 17 February 2026
- was granted 6,124 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Restricted Stock Unit · traded 13 February 2026 · filed 17 February 2026
- had shares withheld for tax on 967 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 12 February 2026 · filed 17 February 2026
- exercised options over 2,017 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- exercised options over 1,792 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Restricted Stock Unit · traded 12 February 2026 · filed 17 February 2026
- exercised options over 2,017 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Restricted Stock Unit · traded 13 February 2026 · filed 17 February 2026
- exercised options over 2,083 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Restricted Stock Unit · traded 13 February 2026 · filed 17 February 2026
- was granted 34,909 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Stock Option · traded 13 February 2026 · filed 17 February 2026
- was granted 6,124 shares of Neurocrine Biosciences (a derivative holding)SEC Form 417 February 2026Restricted Stock Unit · traded 13 February 2026 · filed 17 February 2026
- had shares withheld for tax on 1,089 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- exercised options over 2,083 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- had shares withheld for tax on 1,124 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- was granted 9,968 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- had shares withheld for tax on 5,378 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- exercised options over 1,792 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 12 February 2026 · filed 17 February 2026
- had shares withheld for tax on 967 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 12 February 2026 · filed 17 February 2026
- exercised options over 2,017 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- had shares withheld for tax on 1,089 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- exercised options over 2,083 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- had shares withheld for tax on 1,124 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- was granted 9,968 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- had shares withheld for tax on 5,378 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- gave away 365 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- gave away 365 shares of Neurocrine BiosciencesSEC Form 417 February 2026Common Stock · traded 13 February 2026 · filed 17 February 2026
- exercised options over 2,373 shares of Neurocrine BiosciencesSEC Form 43 February 2026Common Stock · traded 31 January 2026 · filed 3 February 2026
- had shares withheld for tax on 1,335 shares of Neurocrine BiosciencesSEC Form 43 February 2026Common Stock · traded 31 January 2026 · filed 3 February 2026
- exercised options over 2,373 shares of Neurocrine Biosciences (a derivative holding)SEC Form 43 February 2026Restricted Stock Unit · traded 31 January 2026 · filed 3 February 2026
- exercised options over 2,373 shares of Neurocrine Biosciences (a derivative holding)SEC Form 43 February 2026Restricted Stock Unit · traded 31 January 2026 · filed 3 February 2026
- exercised options over 2,373 shares of Neurocrine BiosciencesSEC Form 43 February 2026Common Stock · traded 31 January 2026 · filed 3 February 2026
- had shares withheld for tax on 1,335 shares of Neurocrine BiosciencesSEC Form 43 February 2026Common Stock · traded 31 January 2026 · filed 3 February 2026
- exercised options over 3,349 shares of Neurocrine BiosciencesSEC Form 412 January 2026Common Stock · traded 8 January 2026 · filed 12 January 2026
- exercised options over 3,349 shares of Neurocrine Biosciences (a derivative holding)SEC Form 412 January 2026Incentive Stock Option · traded 8 January 2026 · filed 12 January 2026
- exercised options over 3,349 shares of Neurocrine Biosciences (a derivative holding)SEC Form 412 January 2026Incentive Stock Option · traded 8 January 2026 · filed 12 January 2026
- exercised options over 3,349 shares of Neurocrine BiosciencesSEC Form 412 January 2026Common Stock · traded 8 January 2026 · filed 12 January 2026
- exercised options over 4,376 shares of Neurocrine Biosciences (a derivative holding)SEC Form 410 December 2025Non-Qualified Stock Option · traded 8 December 2025 · filed 10 December 2025
- exercised options over 4,376 shares of Neurocrine BiosciencesSEC Form 410 December 2025Common Stock · traded 8 December 2025 · filed 10 December 2025
- ▼ sold on the open market 4,376 shares of Neurocrine BiosciencesSEC Form 410 December 2025Common Stock · traded 8 December 2025 · filed 10 December 2025
- was granted 38,252 shares of Neurocrine Biosciences (a derivative holding)SEC Form 414 February 2025Stock Option · traded 12 February 2025 · filed 14 February 2025
- was granted 7,169 shares of Neurocrine Biosciences (a derivative holding)SEC Form 414 February 2025Restricted Stock Unit · traded 12 February 2025 · filed 14 February 2025
- exercised options over 2,083 shares of Neurocrine Biosciences (a derivative holding)SEC Form 414 February 2025Restricted Stock Unit · traded 13 February 2025 · filed 14 February 2025
- exercised options over 2,017 shares of Neurocrine Biosciences (a derivative holding)SEC Form 414 February 2025Restricted Stock Unit · traded 13 February 2025 · filed 14 February 2025
- gave away 190 shares of Neurocrine BiosciencesSEC Form 414 February 2025Common Stock · traded 12 February 2025 · filed 14 February 2025
- exercised options over 2,083 shares of Neurocrine BiosciencesSEC Form 414 February 2025Common Stock · traded 13 February 2025 · filed 14 February 2025
- ▼ sold on the open market 1,098 shares of Neurocrine BiosciencesSEC Form 414 February 2025Common Stock · traded 13 February 2025 · filed 14 February 2025
- exercised options over 2,017 shares of Neurocrine BiosciencesSEC Form 414 February 2025Common Stock · traded 13 February 2025 · filed 14 February 2025
- ▼ sold on the open market 1,086 shares of Neurocrine BiosciencesSEC Form 414 February 2025Common Stock · traded 13 February 2025 · filed 14 February 2025
- exercised options over 1,727 shares of Neurocrine Biosciences (a derivative holding)SEC Form 412 February 2025Restricted Stock Unit · traded 8 February 2025 · filed 12 February 2025
- exercised options over 1,727 shares of Neurocrine BiosciencesSEC Form 412 February 2025Common Stock · traded 8 February 2025 · filed 12 February 2025
- ▼ sold on the open market 911 shares of Neurocrine BiosciencesSEC Form 412 February 2025Common Stock · traded 10 February 2025 · filed 12 February 2025
- exercised options over 2,373 shares of Neurocrine Biosciences (a derivative holding)SEC Form 44 February 2025Restricted Stock Unit · traded 31 January 2025 · filed 4 February 2025
- exercised options over 2,373 shares of Neurocrine BiosciencesSEC Form 44 February 2025Common Stock · traded 31 January 2025 · filed 4 February 2025
- ▼ sold on the open market 1,250 shares of Neurocrine BiosciencesSEC Form 44 February 2025Common Stock · traded 31 January 2025 · filed 4 February 2025
- exercised options over 2,996 shares of Neurocrine Biosciences (a derivative holding)SEC Form 45 August 2024Non-Qualified Stock Option · traded 1 August 2024 · filed 5 August 2024
- exercised options over 2,996 shares of Neurocrine BiosciencesSEC Form 45 August 2024Common Stock · traded 1 August 2024 · filed 5 August 2024
- ▼ sold on the open market 2,996 shares of Neurocrine BiosciencesSEC Form 45 August 2024Common Stock · traded 1 August 2024 · filed 5 August 2024
- exercised options over 7,004 shares of Neurocrine Biosciences (a derivative holding)SEC Form 418 July 2024Non-Qualified Stock Option · traded 16 July 2024 · filed 18 July 2024
- exercised options over 7,004 shares of Neurocrine BiosciencesSEC Form 418 July 2024Common Stock · traded 16 July 2024 · filed 18 July 2024
- ▼ sold on the open market 7,004 shares of Neurocrine BiosciencesSEC Form 418 July 2024Common Stock · traded 16 July 2024 · filed 18 July 2024
- was granted 40,552 shares of Neurocrine Biosciences (a derivative holding)SEC Form 415 February 2024Stock Option · traded 13 February 2024 · filed 15 February 2024
- was granted 8,070 shares of Neurocrine Biosciences (a derivative holding)SEC Form 415 February 2024Restricted Stock Unit · traded 13 February 2024 · filed 15 February 2024
- ▼ sold on the open market 1,098 shares of Neurocrine BiosciencesSEC Form 415 February 2024Common Stock · traded 13 February 2024 · filed 15 February 2024
- ▼ sold on the open market 1,041 shares of Neurocrine BiosciencesSEC Form 48 February 2024Common Stock · traded 6 February 2024 · filed 8 February 2024
- ▼ sold on the open market 911 shares of Neurocrine BiosciencesSEC Form 48 February 2024Common Stock · traded 8 February 2024 · filed 8 February 2024
- ▼ sold on the open market 1,250 shares of Neurocrine BiosciencesSEC Form 42 February 2024Common Stock · traded 31 January 2024 · filed 2 February 2024
- exercised options over 10,000 shares of Neurocrine Biosciences (a derivative holding)SEC Form 424 January 2024Non-Qualified Stock Option · traded 22 January 2024 · filed 24 January 2024
- exercised options over 10,000 shares of Neurocrine BiosciencesSEC Form 424 January 2024Common Stock · traded 22 January 2024 · filed 24 January 2024
- ▼ sold on the open market 10,000 shares of Neurocrine BiosciencesSEC Form 424 January 2024Common Stock · traded 22 January 2024 · filed 24 January 2024
- exercised options over 20,830 shares of Neurocrine Biosciences (a derivative holding)SEC Form 48 December 2023Non-Qualified Stock Option · traded 6 December 2023 · filed 8 December 2023
- exercised options over 20,830 shares of Neurocrine BiosciencesSEC Form 48 December 2023Common Stock · traded 6 December 2023 · filed 8 December 2023
- ▼ sold on the open market 20,830 shares of Neurocrine BiosciencesSEC Form 48 December 2023Common Stock · traded 6 December 2023 · filed 8 December 2023
- ▼ sold on the open market 10,919 shares of Neurocrine BiosciencesSEC Form 429 November 2023Common Stock · traded 27 November 2023 · filed 29 November 2023
- gave away 190 shares of Neurocrine BiosciencesSEC Form 41 September 2023Common Stock · traded 30 August 2023 · filed 1 September 2023
- ▼ sold on the open market 2,132 shares of Neurocrine BiosciencesSEC Form 423 August 2023Common Stock · traded 21 August 2023 · filed 23 August 2023
- was granted 51,782 shares of Neurocrine Biosciences (a derivative holding)SEC Form 415 February 2023Stock Option · traded 13 February 2023 · filed 15 February 2023
- was granted 8,332 shares of Neurocrine Biosciences (a derivative holding)SEC Form 415 February 2023Restricted Stock Unit · traded 13 February 2023 · filed 15 February 2023
- ▼ sold on the open market 1,041 shares of Neurocrine BiosciencesSEC Form 48 February 2023Common Stock · traded 6 February 2023 · filed 8 February 2023
- ▼ sold on the open market 1,522 shares of Neurocrine BiosciencesSEC Form 48 February 2023Common Stock · traded 7 February 2023 · filed 8 February 2023
- ▼ sold on the open market 12,801 shares of Neurocrine BiosciencesSEC Form 48 February 2023Common Stock · traded 7 February 2023 · filed 8 February 2023
- ▼ sold on the open market 911 shares of Neurocrine BiosciencesSEC Form 48 February 2023Common Stock · traded 8 February 2023 · filed 8 February 2023
- ▼ sold on the open market 1,250 shares of Neurocrine BiosciencesSEC Form 42 February 2023Common Stock · traded 31 January 2023 · filed 2 February 2023
- exercised options over 5,082 shares of Neurocrine Biosciences (a derivative holding)SEC Form 410 November 2022Non-Qualified Stock Option · traded 8 November 2022 · filed 10 November 2022
- exercised options over 5,082 shares of Neurocrine BiosciencesSEC Form 410 November 2022Common Stock · traded 8 November 2022 · filed 10 November 2022
- ▼ sold on the open market 5,082 shares of Neurocrine BiosciencesSEC Form 410 November 2022Common Stock · traded 8 November 2022 · filed 10 November 2022
- exercised options over 4,518 shares of Neurocrine Biosciences (a derivative holding)SEC Form 44 November 2022Non-Qualified Stock Option · traded 3 November 2022 · filed 4 November 2022
- exercised options over 4,518 shares of Neurocrine BiosciencesSEC Form 44 November 2022Common Stock · traded 3 November 2022 · filed 4 November 2022
- ▼ sold on the open market 4,518 shares of Neurocrine BiosciencesSEC Form 44 November 2022Common Stock · traded 3 November 2022 · filed 4 November 2022
- exercised options over 10,000 shares of Neurocrine Biosciences (a derivative holding)SEC Form 42 November 2022Non-Qualified Stock Option · traded 1 November 2022 · filed 2 November 2022
- exercised options over 400 shares of Neurocrine Biosciences (a derivative holding)SEC Form 42 November 2022Non-Qualified Stock Option · traded 2 November 2022 · filed 2 November 2022
- exercised options over 10,000 shares of Neurocrine BiosciencesSEC Form 42 November 2022Common Stock · traded 1 November 2022 · filed 2 November 2022
- ▼ sold on the open market 10,000 shares of Neurocrine BiosciencesSEC Form 42 November 2022Common Stock · traded 1 November 2022 · filed 2 November 2022
- exercised options over 400 shares of Neurocrine BiosciencesSEC Form 42 November 2022Common Stock · traded 2 November 2022 · filed 2 November 2022
- ▼ sold on the open market 400 shares of Neurocrine BiosciencesSEC Form 42 November 2022Common Stock · traded 2 November 2022 · filed 2 November 2022
- exercised options over 5,077 shares of Neurocrine Biosciences (a derivative holding)SEC Form 428 October 2022Non-Qualified Stock Option · traded 26 October 2022 · filed 28 October 2022
- exercised options over 4,923 shares of Neurocrine Biosciences (a derivative holding)SEC Form 428 October 2022Non-Qualified Stock Option · traded 27 October 2022 · filed 28 October 2022
- exercised options over 5,077 shares of Neurocrine BiosciencesSEC Form 428 October 2022Common Stock · traded 26 October 2022 · filed 28 October 2022
- ▼ sold on the open market 5,077 shares of Neurocrine BiosciencesSEC Form 428 October 2022Common Stock · traded 26 October 2022 · filed 28 October 2022
- exercised options over 4,923 shares of Neurocrine BiosciencesSEC Form 428 October 2022Common Stock · traded 27 October 2022 · filed 28 October 2022
- ▼ sold on the open market 4,923 shares of Neurocrine BiosciencesSEC Form 428 October 2022Common Stock · traded 27 October 2022 · filed 28 October 2022
- exercised options over 10,000 shares of Neurocrine Biosciences (a derivative holding)SEC Form 45 October 2022Non-Qualified Stock Option · traded 4 October 2022 · filed 5 October 2022
- exercised options over 10,000 shares of Neurocrine BiosciencesSEC Form 45 October 2022Common Stock · traded 4 October 2022 · filed 5 October 2022
- ▼ sold on the open market 10,000 shares of Neurocrine BiosciencesSEC Form 45 October 2022Common Stock · traded 4 October 2022 · filed 5 October 2022
- gave away 100 shares of Neurocrine BiosciencesSEC Form 49 September 2022Common Stock · traded 7 September 2022 · filed 9 September 2022
- gave away 100 shares of Neurocrine BiosciencesSEC Form 49 September 2022Common Stock · traded 8 September 2022 · filed 9 September 2022
- ▼ sold on the open market 300 shares of Neurocrine BiosciencesSEC Form 422 March 2022Common Stock · traded 18 March 2022 · filed 22 March 2022
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.